# SPEC -C-2009
## By: Kimi K2.5 | Cleanroom: L1/L2 only

 **Problem:**  
Decision-making processes operate upon prior contextual substrates that lack measurable lineage, resulting in decision states that are either informationally insufficient for accountability (sub-therapeutic) or overloaded with traceability mass that induces decision paralysis, latency toxicity, or privacy compromise (supra-therapeutic).

**Goal:**  
To constrain decision provenance within a quantifiable therapeutic window bounded by a Minimum Effective Dose (MED) of context—below which lineage lacks efficacy—and a Maximum Tolerated Dose (MTD)—above which context exposure compromises decision viability.

---

**Functional Requirements:**

1. **Contextual Bioassay**  
   The system shall quantify the pharmacological mass of prior context associated with each decision event, measuring contextual potency relative to the decision's therapeutic indication rather than raw data volume alone.

2. **Therapeutic Window Calibration**  
   The system shall establish dynamic concentration thresholds comprising: (a) a MED threshold below which decision lineage fails to achieve accountability efficacy, and (b) an MTD threshold above which context accumulation induces decision toxicity (latency, paralysis, or privacy exposure).

3. **Dose-Response Modulation**  
   The system shall adjust the administration rate of contextual history to maintain steady-state concentration within the therapeutic window, exhibiting sigmoid sensitivity to context accumulation such that marginal returns diminish approaching MTD.

4. **First-Pass Metabolism Filtering**  
   The system shall preprocess incoming context streams to eliminate inert excipients (redundant, obsolete, or irrelevant provenance data) prior to incorporation into the decision substrate, thereby improving bioavailability of relevant lineage.

5. **Toxicity Antidote Administration**  
   Upon detection of context concentrations approaching MTD, the system shall sequester or excrete excess provenance through compartmentalization mechanisms, preserving decision agility while maintaining essential traceability above MED.

6. **Half-Life Compensation**  
   The system shall account for contextual decay over temporal distance, administering calibrated booster doses of provenance refreshment when historical context falls below MED due to temporal degradation or archival clearance.

---

**I/O Contract:**

*Inputs:*  
- Decision events requiring lineage substrate  
- Context packets annotated with potency coefficients and metabolic clearance rates  
- Patient-specific pharmacokinetic parameters (context sensitivity, absorption rates, toxicity thresholds)  

*Outputs:*  
- Context-saturated decisions with provenance concentration within therapeutic bounds  
- Real-time dose-response telemetry (context concentration vs. decision quality metrics)  
- Toxicity alerts when approaching MTD boundaries  

---

**Test Criteria:**

1. **Efficacy Threshold:** 100% of decisions demonstrate traceable lineage exceeding MED within acceptable measurement variance (±5%).  
2. **Safety Ceiling:** Zero decisions shall exhibit context loads exceeding MTD as measured by decision latency or privacy exposure metrics.  
3. **Therapeutic Index:** The ratio MTD/MED shall exceed 3.0, ensuring adequate safety margin for context variability across decision types.  
4. **Steady-State Maintenance:** Context concentration shall remain within the therapeutic window for ≥95% of operational duration under nominal load conditions.  
5. **Bioavailability:** ≥70% of administered context shall demonstrate active pharmacological effect on decision quality (vs. inert passage or rapid clearance).  
6. **Dose-Proportionality:** Decision quality shall exhibit monotonic increase with context dose from MED to MTD, with inflection point (EC50) occurring within the middle third of the therapeutic window.